株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

鼻用ドラッグデリバリー技術市場分析レポート:治療用途別(喘息、鼻炎)、剤形別(パウダー、ジェル、スプレー、ドロップ)、容器タイプ別、セグメント予測

Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025

発行 Grand View Research, Inc. 商品コード 785999
出版日 ページ情報 英文 90 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.34円で換算しております。
Back to Top
鼻用ドラッグデリバリー技術市場分析レポート:治療用途別(喘息、鼻炎)、剤形別(パウダー、ジェル、スプレー、ドロップ)、容器タイプ別、セグメント予測 Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025
出版日: 2019年01月08日 ページ情報: 英文 90 Pages
概要

当レポートでは、世界の鼻用ドラッグデリバリー技術市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査方法と調査範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

第4章 市場の定義

第5章 業界見通し

  • 市場変数分析
  • 阻害因子分析

第6章 ビジネス環境分析

  • SWOT分析
  • ポーターズファイブフォース分析

第7章 剤形別ビジネス分析

  • 動向分析
  • 鼻スプレー
  • ドロップ
  • ジェル
  • パウダー

第8章 容器タイプ別ビジネス分析

  • 動向分析
  • 加圧容器
  • 非加圧容器

第9章 治療用途別ビジネス分析

  • 動向分析
  • 鼻づまり
  • 鼻炎
  • 喘息
  • その他

第10章 地域別ビジネス分析

  • 動向分析
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第11章 企業プロファイル

  • 企業プロファイル
    • GlaxoSmithkline plc.
    • AstraZeneca
    • Pfizer, Inc.
    • OptiNose
    • Becton, Dickson and Company
    • Promius Pharma
    • B.F. Ascher & Company, Inc.
    • Cadila Pharmaceuticals
    • Douglas NZ
    • ENT Technologies Pty. Ltd.
    • Pendopharm
    • NAVEH Pharma
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Nasal Drug Delivery Technology market, by dosage form 2014 - 2025 (USD Billion)
  • Table 3 North America Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 4 North America Nasal Drug Delivery Technology market, by therapeutic application 2014 - 2025 (USD Billion)
  • Table 5 U.S. Nasal Drug Delivery Technology market, by dosage types 2014 - 2025 (USD Billion)
  • Table 6 U.S. Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 7 U.S. Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 8 Canada Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 9 Canada Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 10 Canada Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 11 Europe Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 12 Europe Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 13 Europe Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 14 Germany Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 15 Germany Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 16 Germany Nasal Drug Delivery Technology market, by therapeutic application 2014 - 2025 (USD Billion)
  • Table 17 U.K. Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 18 U.K. Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 19 U.K. Nasal Drug Delivery Technology market, by therapeutic application 2014 - 2025 (USD Billion)
  • Table 20 Asia Pacific Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 21 Asia Pacific Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 22 Asia Pacific Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 23 Japan Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 24 Japan Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 25 Japan Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 26 China Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 27 China Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 28 China Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 29 India Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 30 India Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 31 India Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 32 Latin America Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 33 Latin America Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 34 Latin America Nasal Drug Delivery Technology market, by distribution channel 2014 - 2025 (USD Billion)
  • Table 35 Brazil Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 36 Brazil Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 37 Brazil Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 38 Mexico Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 39 Mexico Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 40 Mexico Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 41 MEA Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 42 MEA Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 43 MEA Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)
  • Table 44 South Africa Nasal Drug Delivery Technology market, by dosage forms 2014 - 2025 (USD Billion)
  • Table 45 South Africa Nasal Drug Delivery Technology market, by container type 2014 - 2025 (USD Billion)
  • Table 46 South Africa Nasal Drug Delivery Technology market, by therapeutic applications 2014 - 2025 (USD Billion)

List of Figures

  • Fig.1 Nasal Drug Delivery Technology market, 2017
  • Fig.2 Nasal Drug Delivery Technology market segmentation
  • Fig.3 Nasal Drug Delivery Technology market driver impact
  • Fig.4 Nasal Drug Delivery Technology market driver impact
  • Fig.5 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig.6 Porter's Five Forces Analysis
  • Fig.7 Nasal Drug Delivery Technology market: Dosage form outlook and key takeaways
  • Fig.8 Nasal Drug Delivery Technology market: Dosage Form Movement Analysis
  • Fig.9 Nasal sprays market estimates and forecast, 2014 - 2025
  • Fig.10 Nasal drops market estimates and forecast, 2014 - 2025
  • Fig.11 Nasal gels market estimates and forecast, 2014 - 2025
  • Fig.12 Nasal powder market estimates and forecast, 2014 - 2025
  • Fig.13 Nasal Drug Delivery Technology market: Container type outlook and key takeaways
  • Fig.14 Nasal Drug Delivery Technology market: Container Type Movement Analysis
  • Fig.15 Pressurized containers market estimates and forecast, 2014 - 2025
  • Fig.16 Non-pressurized containers market estimates and forecast, 2014 - 2025
  • Fig.17 Nasal Drug Delivery Technology market: Therapeutic application outlook and key takeaways
  • Fig.18 Nasal Drug Delivery Technology market: Therapeutic Application Movement Analysis
  • Fig.19 Nasal congestion market estimates and forecast, 2014 - 2025
  • Fig.20 Rhinitis market estimates and forecast, 2014 - 2025
  • Fig.21 Asthma market estimates and forecast, 2014 - 2025
  • Fig.22 Others market estimates and forecast, 2014 - 2025
  • Fig.23 Nasal Drug Delivery Technology market: Regional outlook and key takeaways
  • Fig.24 Nasal Drug Delivery Technology market: Regional movement analysis
  • Fig.25 North America
  • Fig.26 North America. market estimates and forecast, 2014 - 2025
  • Fig.27 U.S. market estimates and forecast, 2014 - 2025
  • Fig.28 Canada market estimates and forecast, 2014 - 2025
  • Fig.29 Europe
  • Fig.30 Europe market estimates and forecast, 2014 - 2025
  • Fig.31 Germany market estimates and forecast, 2014 - 2025
  • Fig.32 U.K. market estimates and forecast, 2014 - 2025
  • Fig.33 Asia-Pacific
  • Fig.34 Asia-Pacific market estimates and forecast, 2014 - 2025
  • Fig.35 Japan market estimates and forecast, 2014 - 2025
  • Fig.36 China. market estimates and forecast, 2014 - 2025
  • Fig.37 India market estimates and forecast, 2014 - 2025
  • Fig.38 Latin America
  • Fig.39 Latin America market estimates and forecast, 2014 - 2025
  • Fig.40 Brazil market estimates and forecast, 2014 - 2025
  • Fig.41 Mexico market estimates and forecast, 2014 - 2025
  • Fig.42 Middle East & Africa
  • Fig.43 MEA market estimates and forecast, 2014 - 2025
  • Fig.44 South Africa market estimates and forecast, 2014 - 2025
  • Fig.45 Company profile
目次
Product Code: GVR-2-68038-740-7

The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR, according to a new report by Grand View Research, Inc. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy's Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

Further key findings from the study suggest:

Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases

On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy

Non-pressurized containers segment led the market in 2017 due to continous development in nasal powders and gel products

Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence

Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.

Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Scope and Assumptions
  • 1.3 List of Tables

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation

Chapter 4 Market Definitions

Chapter 5 Industry Outlook

  • 5.1 Market Variable Analysis
    • 5.1.1 Increasing preference for nasal drug delivery technology
    • 5.1.2 Growing incidence of chronic diseases
    • 5.1.3 Growing geriatric population
  • 5.2 Market Restraint Analysis
    • 5.2.1 Complications associated with the overuse of nasal powders

Chapter 6 Business Environment Analysis

  • 6.1 SWOT Analysis; By factor (Political & legal, economic and technological)
  • 6.2 Porter's Five Forces Analysis

Chapter 7 Dosage Forms Business Analysis

  • 7.1 Nasal Drug Delivery Technology market: Dosage Forms Movement Analysis
  • 7.2 Nasal Spray
    • 7.2.1 Nasal sprays market estimates and forecast, 2014 - 2025
  • 7.3 Nasal Drop
    • 7.3.1 Nasal drops market estimates and forecast, 2014 - 2025
  • 7.4 Nasal Gel
    • 7.4.1 Nasal gels market estimates and forecast, 2014 - 2025
  • 7.5 Nasal Powder
    • 7.5.1 Nasal powder market estimates and forecast, 2014 - 2025

Chapter 8 Container Type Business Analysis

  • 8.1 Nasal Drug Delivery Technology market: Container Type Movement Analysis
  • 8.2 Pressurized container
  • 8.3 Pressurized container market estimates and forecast, 2014 - 2025
  • 8.4 Non-pressurized container
  • 8.5 Non-pressurized container market estimates and forecast, 2014 - 2025

Chapter 9 Therapeutic Application Business Analysis

  • 9.1 Nasal Drug Delivery Technology market: Therapeutic Application Movement Analysis
  • 9.2 Nasal Congestion
    • 9.2.1 Nasal congestion market estimates and forecast, 2014 - 2025
  • 9.3 Rhinitis
    • 9.3.1 Rhinitis market estimates and forecast, 2014 - 2025
  • 9.4 Asthma
    • 9.4.1 Asthma market estimates and forecast, 2014 - 2025
  • 9.5 Others
    • 9.5.1 Others market estimates and forecast, 2014 - 2025

Chapter 10 Regional Business Analysis

  • 10.1 Nasal Drug Delivery Technology Market: Regional Movement Analysis
  • 10.2 North America.
    • 10.2.1 North America market estimates and forecast, 2014 - 2025
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. market estimates and forecast, 2014 - 2025
    • 10.2.3 Canada
      • 10.2.3.1 Canada market estimates and forecast, 2014 - 2025
  • 10.3 Europe
    • 10.3.1 Europe market estimates and forecast, 2014 - 2025
    • 10.3.2 Germany
    • 10.3.3 Germany market estimates and forecast, 2014 - 2025
    • 10.3.4 U.K.
    • 10.3.5 U.K. market estimates and forecast, 2014 - 2025
  • 10.4 Asia-Pacific
    • 10.4.1 Asia-Pacific market estimates and forecast, 2014 - 2025
    • 10.4.2 Japan
      • 10.4.2.1 Japan market estimates and forecast, 2014 - 2025
    • 10.4.3 China
      • 10.4.3.1 China market estimates and forecast, 2014 - 2025
    • 10.4.4 India
      • 10.4.4.1 India market estimates and forecast, 2014 - 2025
  • 10.5 Latin America
    • 10.5.1 Latin America market estimates and forecast, 2014 - 2025
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil market estimates and forecast, 2014 - 2025
    • 10.5.3 Mexico
      • 10.5.3.1 Market estimates and forecast, 2014 - 2025
  • 10.6 Middle East and Africa
    • 10.6.1 Middle-East and Africa market estimates and forecast, 2014 - 2025
    • 10.6.2 South Africa
    • 10.6.3 South Africa market estimates and forecast, 2014 - 2025

Chapter 11 Company Profiles

  • 11.1 Company Profiles
    • 11.1.1 GlaxoSmithkline plc.
      • 11.1.1.1 Company overview
      • 11.1.1.2 Financial Performance
      • 11.1.1.3 Product benchmarking
      • 11.1.1.4 Strategic initiatives
    • 11.1.2 AstraZeneca
      • 11.1.2.1 Company overview
      • 11.1.2.2 Financial performance
      • 11.1.2.3 Product benchmarking
      • 11.1.2.4 Strategic initiatives
    • 11.1.3 Pfizer, Inc.
      • 11.1.3.1 Company overview
      • 11.1.3.2 Financial performance
      • 11.1.3.3 Product benchmarking
    • 11.1.4 OptiNose
      • 11.1.4.1 Company overview
      • 11.1.4.2 Product benchmarking
      • 11.1.4.3 Strategic initiatives
    • 11.1.5 Becton, Dickson and Company
      • 11.1.5.1 Company overview
      • 11.1.5.2 FINANCIAL PERFORMANCE
      • 11.1.5.3 Product benchmarking
    • 11.1.6 Promius Pharma
      • 11.1.6.1 Company overview
      • 11.1.6.2 FINANCIAL PERFORMANCE
      • 11.1.6.3 Product Benchmarking
      • 11.1.6.4 strategic initiatives
    • 11.1.7 B.F. Ascher & Company, Inc.
      • 11.1.7.1 Company overview
      • 11.1.7.2 Product benchmarking
    • 11.1.8 Cadila Pharmaceuticals
      • 11.1.8.1 Company overview
      • 11.1.8.2 Financial performance
      • 11.1.8.3 Product Benchmarking
    • 11.1.9 Douglas NZ
      • 11.1.9.1 Company overview
      • 11.1.9.2 Product benchmarking
    • 11.1.10 ENT Technologies Pty. Ltd.
      • 11.1.10.1 Company Overview
      • 11.1.10.2 Product Benchmarking
    • 11.1.11 Pendopharm
      • 11.1.11.1 Company Overview
      • 11.1.11.2 Product Benchmarking
    • 11.1.12 NAVEH Pharma
      • 11.1.12.1 Company Overview
      • 11.1.12.2 Product Benchmarking
Back to Top